Eli Lilly and Company: Are All Profits Healthy?
商品編號：W46376
出版日期：2025/10/24
再版日期：
商品來源：
商品主題：General Management/Strategy; Strategy
商品類型：Case (Pub Mat)
涵蓋議題：Health care, Ethics, Pricing, Strategy
難易度：4 - Undergraduate/MBA
內容長度：16 頁
地域：United States
產業：Health Care Services
事件年度：2023
In May 2023, the CEO of pharmaceutical company Eli Lilly was called before the US Senate to testify on the rising costs of insulin prices in the United States. At the time of the hearing, Eli Lilly’s insulin prices had increased by 400% over the past 20 years, a much higher rate than targeted inflation (2%). In the face of rising public resentment and potential legislative changes, Eli Lilly was forced to either justify or reckon with its pricing strategy. Taking into account economic, ethical, and legal factors, what were the potential consequences of either changing or maintaining its pricing strategy?
教學手冊：Eli Lilly and Company: Are All Profits Healthy? - Teaching Note
補充材料：
|